Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2026)
Aligos Therapeutics (ALGS) reported EBITDA Margin of 815.19% for Q1 2026, down 1466857.0% on a YoY basis from N/an in Q1 2025, and up 93.07% quarter-over-quarter from 11756.21% in Q4 2025.
Aligos Therapeutics (ALGS) EBITDA Margin (2021 - 2026) Analysis & Trends
Aligos Therapeutics has reported EBITDA Margin for 6 years, with the latest figure at 815.19% in Q1 2026.
- For the quarter ending Q1 2026, EBITDA Margin fell 1466857.0% year-over-year to 815.19%; the trailing twelve-month figure through Mar 2026 stood at 1919.87% (down 26904.0% YoY), and the FY2025 full-year result was 1105.95%, up 253030.0% from the prior year.
- EBITDA Margin for Q1 2026 stood at 815.19%, up from 11756.21% in the prior quarter.
- The five-year high for EBITDA Margin was 13853.38% in Q1 2025, with the low at 13576.9% in Q4 2024.
- Historically, EBITDA Margin has averaged 1945.18% across 5 years, with a median of 884.9% in 2023.
- Annual changes were most pronounced in 2025 — EBITDA Margin jumped 1888681 bps — and 2026, when it plunged 1466857 bps.
- Aligos Therapeutics' EBITDA Margin stood at 611.93% in 2022, then slipped by 19 bps to 729.09% in 2023, then slumped by 1762 bps to 13576.9% in 2024, then grew by 13 bps to 11756.21% in 2025, then surged by 93 bps to 815.19% in 2026.
- The last three EBITDA Margin figures came in at 815.19% (Q1 2026), 11756.21% (Q4 2025), and 4251.28% (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBITDA Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 719,706.53 Bn | 719,706.50 Bn | - | - |
| 2 | Belite Bio | 55,800.00 Bn | 55,800.00 Bn | - | - |
| 3 | Quantum Biopharma | 18,182.30 Bn | 18,182.29 Bn | - | - |
| 4 | Legend Biotech | 3,154.00 Bn | 3,153.71 Bn | 242.10 Mn | -6.43% |
| 5 | Akari Therapeutics | 1,844.30 Bn | 1,844.29 Bn | - | - |
| 6 | Evaxion A | 1,567.96 Bn | 1,567.94 Bn | - | - |
| 7 | Psyence Biomedical | 251.43 Bn | 251.42 Bn | - | - |
| 8 | Vertex Pharmaceuticals | 112.56 Bn | 105.31 Bn | 2.59 Bn | 38.10% |
| 9 | Abivax | 94.37 Bn | 94.37 Bn | - | - |
| 10 | Aligos Therapeutics | 51.70 Mn | -28.13 Mn | - | -815.19% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -815.19% |
| Dec 31, 2025 | -11,756.21% |
| Sep 30, 2025 | -4,251.28% |
| Jun 30, 2025 | -1,646.63% |
| Mar 31, 2025 | 13,853.38% |
| Dec 31, 2024 | -13,576.90% |
| Sep 30, 2024 | -1,534.08% |
| Jun 30, 2024 | 478.70% |
| Mar 31, 2024 | -5,033.43% |
| Dec 31, 2023 | -729.09% |
| Sep 30, 2023 | -837.56% |
| Jun 30, 2023 | -437.66% |
| Mar 31, 2023 | -884.90% |
| Dec 31, 2022 | -611.93% |
| Mar 31, 2022 | -1,394.90% |
| Dec 31, 2021 | -10,085.01% |
| Sep 30, 2021 | -2,155.04% |
| Jun 30, 2021 | -1,931.52% |
| Mar 31, 2021 | -3,045.38% |